Rule 4.2A

# Appendix 4E Preliminary Final Report

## 1. Company details

Name of entity

#### Pro Medicus Limited ABN or equivalent Financial year ended Financial year ended company reference ('current period') ('previous period') 25 006 194 752 30 June 2015 30 June 2014

### 2. Results for announcement to the market

ASX Listing Rules Ref		2015 A\$'000	2014 A\$'000	% change
2.1	Revenue from continuing operations	17,577	14,447	21.7%
2.2	Profit/(Loss) from ordinary activities after tax attributable to members	3,217	1,509	113.2%
2.3	Net Profit/(Loss) for the period attributable to members	3,217		
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Up 113.2%		

2.4	Dividends (distributions)	Amount per security	Unfranked amount per security
	Unfranked dividend amount per security		
	Final Dividend	1.0 cents	1.0 cents
	Interim dividend	1.0 cents	1.0 cents
2.5	Record date for Final dividends	11 September 2015	
	Payment date for Final dividends	2 October 2015	

2.6	Australia	
	The Group's Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.	
	The Group's Australian revenue was 1.9% above last year' as a result of new sales of both the Visage PACS and Visage RIS products with many sales being for the combined product offering.	
	Promedicus.net, the company's e-health offering, continued to hold its strong market position despite increasing competition.	
	North America	
	The growing North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 67.2% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream.	
	Europe	
	The Group's employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group's European operations. Revenue from our European operations decreased by 16.3% from last year, due to lower OEM sales.	
	Financials	
	Reported profit after tax for the period was \$3.22m an increase of \$1.71m (113.2%) from the previous year.	
	Full year revenue of the Group from continuing operations, increased from \$14.45m to \$17.58m, an increase of 21.7%.	
	The key driver of the profit increase was the significant improvement in the performance of the North American operations supplemented by a modest increase in Australian sales.	
	As the Group's costs are relatively fixed, an increase in sales has a positive impact on profitability.	
	Shareholder Returns	
	The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.	
3.	Statement of Comprehensive Income	
	Please refer to the Statement of Comprehensive Income in the attached Financial Statements.	
4.	Statement of Financial Position	
	Please refer to the Statement of Financial Position in the attached Financial Statements.	
5.	Statement of cash flows	
	Please refer to the Statement of cash flows in the attached Financial Statements.	

•			
6.	Details of Dividends	2015 \$'000	2014 \$'000
	Final Dividend		·
	An unfranked Final Dividend of 1.0 cents (2014: 1.0 cents) per share will be paid on 2 October 2015.	1,002	1,002
	Current Year Interim		
	An unfranked Interim Dividend of 1.0 cents (2014: 1.0 cents) per share was paid on 20 March 2015.	1,002	1.002
	No foreign sourced dividend or distribution is included in either dividends.	the interim or f	inal
7.	Dividend or Distribution reinvestment plans		
	There are no dividend or distribution reinvestment plans in ope	ration.	
8.	Statement of Retained Earnings		
	Please refer to Statement of Changes in Equity in the attached	Financial State	ements.
9.	Net Tangible Assets per security 20	)15	2014
	Net Tangible Assets per security \$0	.13	\$0.13
10.	Details of entities over which control has been gained or lost during the period		-
	There are no entities over which control has been gained or los	st during the pe	riod
11.	Associates and joint venture entities		
	There are no associates or joint venture entities		
12.	Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.		
	Please refer to section 2.6		
13.	Foreign Entity accounting standards		
	Australian Accounting Standards & International Financial Repo	orting Standard	s

14.	Commentary on results for the period. The earnings per security and the nature of any dilution aspects. Please refer to Note 8 of the attached Financial Statements.		
	<b>Returns to shareholders including distributions and buy backs.</b> Please refer to Note 9 of the attached Financial Statements.		
	Significant features of operating performance. Please refer to section 2.6.		
	The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.		
	<b>Discussion of trends in performance.</b> Please refer to section 2.6.		
15.	Audit Statement		
	This report is based on accounts to which one of the following applies.		
	(Tick one) ∑ The ⁺accounts have been ☐ The ⁺accounts have been subject to audited. review.		
	☐ The ⁺accounts are in the ☐ The ⁺accounts have not yet been process of being audited.		

Sign here:

Date: 21 August 2015

Jam Alup of > 0

Print name:	Sam Hupert
	Chief Executive Officer